First Tracks Biotherapeutics/$TRAX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About First Tracks Biotherapeutics
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
- Ticker
- $TRAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- San Diego, United States
- Website
- www.firsttracksbio.com
TRAX Metrics
BasicAdvanced
$1.9B
-
-$4.53
-
-
Price and volume
Market cap
$1.9B
52-week high
$49.91
52-week low
$14.72
Average daily volume
1M
Financial strength
Current ratio
14.28
Quick ratio
13.906
Long term debt to equity
0.011
Total debt to equity
0.026
Profitability
EBITDA (TTM)
-169.075
Management effectiveness
Valuation
Price to book
9.46
Price to tangible book (TTM)
9.46
Price to free cash flow (TTM)
-12.885
Free cash flow yield (TTM)
-7.76%
Free cash flow per share (TTM)
-3.499
Growth
What the Analysts think about TRAX
Analyst ratings (Buy, Hold, Sell) for First Tracks Biotherapeutics stock.
Analyst projections of the future price of First Tracks Biotherapeutics stock.
Bulls say / Bears say
ANB033’s Phase 1b celiac gluten-challenge cohort showed statistically significant benefits on intestinal-damage measures and symptoms versus placebo. The results provide early clinical proof of concept for the company’s lead programme. (First Tracks Biotherapeutics)
The same small study reported no serious or severe adverse events, and no ANB033-treated patients stopped treatment because of an adverse event. That is an encouraging early tolerability profile for a treatment intended for chronic use. (First Tracks Biotherapeutics)
The pipeline offers further potential catalysts: celiac mucosal-healing data are expected in Q1 2027, with eosinophilic oesophagitis data in Q3 2027 and two additional Phase 2 studies planned for the first half of 2027. Positive results beyond the first celiac cohort could broaden ANB033’s opportunity across several diseases. (First Tracks Biotherapeutics)
The celiac efficacy result came from only 32 evaluable patients in a short Phase 1b gluten-challenge study. It does not yet establish that the benefit will hold in a larger trial or in the separate mucosal-healing cohort, whose data are due in Q1 2027. (First Tracks Biotherapeutics)
The company has agreed to issue 6.1 million shares in a $200 million private placement. Against the 35.4 million shares outstanding at the end of June, that represents potential dilution of roughly 17% before allowing for other share changes. (First Tracks Biotherapeutics, SEC)
The company is assessing strategic options for rosnilimab and has not yet settled on a development approach for ANB101. That leaves these programmes’ contribution uncertain and makes the investment case more dependent on ANB033. (First Tracks Biotherapeutics)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
TRAX Financial Performance
Revenues and expenses
TRAX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TRAX News
AllArticlesVideos
First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals
MarketBeat3 weeks ago
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
Benzinga3 weeks ago
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
Benzinga3 months ago
Funds containing TRAX
Fund name | Fund size | $TRAX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.